NASDAQ:GMTX Gemini Therapeutics (GMTX) Stock Forecast, Price & News $48.91 -0.09 (-0.18%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$47.84▼$49.2450-Day Range$45.61▼$55.9352-Week Range$1.16▼$14.10Volume87,330 shsAverage Volume189,291 shsMarket Capitalization$2.12 billionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Gemini Therapeutics (NASDAQ:GMTX) StockGemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Read More GMTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMTX Stock News HeadlinesSeptember 18, 2023 | americanbankingnews.comComparing Gemini Therapeutics (NASDAQ:GMTX) & Collegium Pharmaceutical (NASDAQ:COLL)June 24, 2023 | benzinga.com(SPAC) Special Purpose Acquisition Investigation: PRDS, GMTX, SNTI, TNGX - Contact Shareholder Rights Law Firm Johnson FistelSeptember 24, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.June 1, 2023 | barrons.comBronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Gemini Therapeutics, Inc. (GMTX) InvestigationJanuary 13, 2023 | markets.businessinsider.comThe Winklevoss' Gemini terminates its yield product as dispute between the crypto exchange and DCG escalatesJanuary 1, 2023 | usatoday.comGemini HoroscopeDecember 27, 2022 | finance.yahoo.comDisc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic ProtoporphyriaOctober 31, 2022 | finance.yahoo.comDisc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)September 24, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 27, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBTX, PBFX, EVOP, GMTXSeptember 26, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFYSeptember 16, 2022 | markets.businessinsider.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMTX, RMED, LOTZSeptember 6, 2022 | markets.businessinsider.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, DRE, PLD, GMTX, SAFEAugust 25, 2022 | apnews.comThe M&A Class Action Firm Announces the Investigation of Gemini Therapeutics, Inc. – GMTXAugust 24, 2022 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds, LOTZ, GMTX, AAWW, and CCXI Shareholders About Its Ongoing InvestigationsAugust 12, 2022 | apnews.comGEMINI THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GMTX and Encourages Investors to Contact the FirmAugust 12, 2022 | marketwatch.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Gemini Therapeutics, Inc. MergerAugust 11, 2022 | benzinga.comSHAREHOLDER ALERT: Weiss Law Investigates Gemini Therapeutics, Inc.August 11, 2022 | apnews.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZAugust 11, 2022 | apnews.comGMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to ShareholdersAugust 10, 2022 | apnews.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Gemini Therapeutics, Inc. (Nasdaq – GMTX)August 10, 2022 | finance.yahoo.comBlood disorder startup goes public by merging with embattled biotechAugust 10, 2022 | seekingalpha.comGemini stock soars 35% on merger with Disc Medicine in all-stock dealAugust 10, 2022 | nasdaq.comGemini Therapeutics, Disc Medicine Announce All-stock MergerAugust 10, 2022 | finance.yahoo.comGemini Therapeutics and Disc Medicine Announce Merger AgreementApril 15, 2022 | finance.yahoo.comInsider Buying: Braden Leonard Just Spent US$75k On Gemini Therapeutics, Inc. (NASDAQ:GMTX) SharesApril 12, 2022 | finance.yahoo.comGemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?See More Headlines Receive GMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GMTX Company Calendar Last Earnings11/15/2021Today9/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GMTX CUSIPN/A CIK1816736 Webwww.geminitherapeutics.com Phone415-877-4887FaxN/AEmployees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.78% Return on Assets-35.88% Debt Debt-to-Equity RatioN/A Current Ratio71.49 Quick Ratio71.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book16.92Miscellaneous Outstanding Shares43,328,000Free Float37,739,000Market Cap$2.12 billion OptionableOptionable Beta-0.12 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Georges Gemayel C.F.A. (Age 62)Ph.D., Interim Pres & CEO and Exec. Chairperson Comp: $256.73kMr. Brian Piekos (Age 46)Chief Bus. Officer, CFO, Principal Accounting & Principal Financial Officer Comp: $549.73kMr. Jason Patrick Meyenburg M.B.A. (Age 44)M.D., Advisor Comp: $715.96kMr. Patrick Truesdell (Age 41)VP of Fin. & Controller Key CompetitorsVentyx BiosciencesNASDAQ:VTYXHarmony BiosciencesNASDAQ:HRMYAmphastar PharmaceuticalsNASDAQ:AMPHSchrödingerNASDAQ:SDGRGalapagosNASDAQ:GLPGView All CompetitorsInsidersBraden Michael LeonardSold 22,500 sharesTotal: $47,025.00 ($2.09/share)View All Insider Transactions GMTX Stock - Frequently Asked Questions How have GMTX shares performed in 2023? Gemini Therapeutics' stock was trading at $19.89 at the beginning of the year. Since then, GMTX shares have increased by 145.9% and is now trading at $48.91. View the best growth stocks for 2023 here. How were Gemini Therapeutics' earnings last quarter? Gemini Therapeutics, Inc. (NASDAQ:GMTX) released its earnings results on Monday, November, 15th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.04. What is Gemini Therapeutics' stock symbol? Gemini Therapeutics trades on the NASDAQ under the ticker symbol "GMTX." How do I buy shares of Gemini Therapeutics? Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Gemini Therapeutics' stock price today? One share of GMTX stock can currently be purchased for approximately $48.91. How much money does Gemini Therapeutics make? Gemini Therapeutics (NASDAQ:GMTX) has a market capitalization of $2.12 billion. The company earns $-71,870,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. How can I contact Gemini Therapeutics? Gemini Therapeutics' mailing address is C/O FORESITE CAPITAL 600 MONTGOMERY ST SUITE 4500, SAN FRANCISCO CA, 94111. The official website for the company is www.geminitherapeutics.com. The company can be reached via phone at 415-877-4887 or via email at gemini@argotpartners.com. This page (NASDAQ:GMTX) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.